| Original language | English (US) |
|---|---|
| Pages (from-to) | 509-511 |
| Number of pages | 3 |
| Journal | Movement Disorders |
| Volume | 38 |
| Issue number | 3 |
| DOIs | |
| State | Published - Mar 2023 |
Bibliographical note
Funding Information:is funded by the Reta Lila Weston Institute of Neurological Studies, Institute of Neurology, University College London, and reports consultancies from Britannia Pharmaceuticals and BIAL. He also reports grants and/or research support from the Frances and Renee Hock Fund and honoraria from Britannia Pharmaceuticals, Profile Pharma, UCB, Roche, BIAL, STADA, NordicInfu Care, and NeuroDerm. Andrew J. Lees:
Funding Information:
received funding as site investigator from AbbVie Inc., Alexion Pharmaceuticals, Ultragenix Inc., and UC WorldMeds; has also received funding from the National Institute of Environmental Health Sciences (R01 ES031106 01A1). Jeff M. Bronstein:
Funding Information:
received research grants from Neuroderm, Medtronic, and Parkinson Vereniging. Rob M.A. de Bie:
Funding Information:
consultant to Medtronic; received honoraria for speaking from St. Jude; and obtained grants from DFG (German Research Foundation). Joachim K. Krauss:
Funding Information:
grants from Swiss National Science Foundation, Roger de Spoelberch Foundation, Bertarelli Foundation, Annemarie Opprecht Foundation, Parkinson Schweiz, The Michael J. Fox Foundation, Aleva Neurotherapeutics, and Boston Scientific; and personal fees (lecturing fees to employing institution/travel expenses to scientific meetings) from Boston Scientific, Bial, and Zambon outside the submitted work. Paul Krack:
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS